Oruka Therapeutics (STU:HQ1) Common Stock: €0.05 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HQ1 Oruka Therapeutics Inc STU:HQ1
20 GF Score
Price €77.00
! 1 Warning Sign
View Full Analysis

What is Oruka Therapeutics Common Stock?

Oruka Therapeutics STU:HQ1 -1.91% 20 Common Stock is €0.05 Mil as of Jun. 2026. GuruFocus rates STU:HQ1 with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Oruka Therapeutics's quarterly common stock increased from Dec. 2025 (€0.04 Mil) to Mar. 2026 (€0.04 Mil) and increased from Mar. 2026 (€0.04 Mil) to Jun. 2026 (€0.05 Mil).

Oruka Therapeutics's annual common stock increased from . 20 (€0.00 Mil) to Dec. 2024 (€0.04 Mil) and increased from Dec. 2024 (€0.04 Mil) to Dec. 2025 (€0.04 Mil).

Oruka Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Oruka Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics Common Stock Chart

Oruka Therapeutics Annual Data
Trend Dec24 Dec25
Common Stock
0.04 0.04

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.04 0.04 0.04 0.05
STU:HQ1
20GF Score
Oruka Therapeutics Inc STU:HQ1
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oruka Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0.05 Mil mean?
Oruka Therapeutics (STU:HQ1) has a Common Stock of €0.05 Mil as of Jun. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Oruka Therapeutics and its competitors.
Is Oruka Therapeutics' Common Stock too high?
Oruka Therapeutics' current Common Stock is €0.05 Mil. Overall, Oruka Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Oruka Therapeutics' Common Stock compare to COGT and MIRM?
Oruka Therapeutics' Common Stock of €0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Oruka Therapeutics and its competitors. Oruka Therapeutics's current Common Stock is €0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oruka Therapeutics stock overvalued right now?
Oruka Therapeutics (STU:HQ1) has a current Common Stock of €0.05 Mil. The current Common Stock is €0.05 Mil. Oruka Therapeutics' overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Oruka Therapeutics (STU:HQ1), the current Common Stock is €0.05 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oruka Therapeutics Business Description

Other Exchanges ORKA:USA
Address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
20GF Score

Get the complete analysis for STU:HQ1

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price